Rifampicin alone may be enough: is it time to abandon the classic oral clindamycin-rifampicin combination for hidradenitis suppurativa?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

1. Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
   Article
2. Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review.Journal of clinical medicine · 2022
   Review
3. [Hidradenitis suppurativa/acne inversa in daily practice].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021
   Review
4. The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa-Light at the End of the Microbiological Tunnel.International journal of molecular sciences · 2020
   Review
5. Skin manifestations in spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2020
   Review
6. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.Therapeutic advances in chronic disease · 2019
   Review

Corrections and comments

• Commented on by
  Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa?2019
• Commented on by
  Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? Reply from the authors.2019
• Comment on
  Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic.2019
• Comment on
  Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: a strategy to reduce side-effects, improving patients' compliance.2019

Authors and funding

3 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as